Bustanji Y - Search Results

1

Docking simulations and in vitro assay unveil potent inhibitory action of papaverine against protein tyrosine phosphatase 1B.

Bustanji Y, Taha MO, Al-Masri IM, Mohammad MK. Bustanji Y, et al. Biol Pharm Bull. 2009 Apr;32(4):640-5. doi: 10.1248/bpb.32.640. Biol Pharm Bull. 2009. PMID: 19336898 Free article.

2

COVID-19 Vaccines, Effectiveness, and Immune Responses.

Abufares HI, Oyoun Alsoud L, Alqudah MAY, Shara M, Soares NC, Alzoubi KH, El-Huneidi W, Bustanji Y, Soliman SSM, Semreen MH. Abufares HI, et al. Among authors: bustanji y. Int J Mol Sci. 2022 Dec 6;23(23):15415. doi: 10.3390/ijms232315415. Int J Mol Sci. 2022. PMID: 36499742 Free PMC article. Review.

3

Berberine potently inhibits protein tyrosine phosphatase 1B: investigation by docking simulation and experimental validation.

Bustanji Y, Taha MO, Yousef AM, Al-Bakri AG. Bustanji Y, et al. J Enzyme Inhib Med Chem. 2006 Apr;21(2):163-71. doi: 10.1080/14756360500533026. J Enzyme Inhib Med Chem. 2006. PMID: 16789430

4

Effect of ionic crosslinking on the drug release properties of chitosan diacetate matrices.

Aiedeh KM, Taha MO, Al-Hiari Y, Bustanji Y, Alkhatib HS. Aiedeh KM, et al. Among authors: bustanji y. J Pharm Sci. 2007 Jan;96(1):38-43. doi: 10.1002/jps.20764. J Pharm Sci. 2007. PMID: 17031867

5

Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.

Taha MO, Bustanji Y, Al-Bakri AG, Yousef AM, Zalloum WA, Al-Masri IM, Atallah N. Taha MO, et al. Among authors: bustanji y. J Mol Graph Model. 2007 Mar;25(6):870-84. doi: 10.1016/j.jmgm.2006.08.008. Epub 2006 Sep 3. J Mol Graph Model. 2007. PMID: 17035054

6

Evaluation of immunosuppression induced by metronidazole in Balb/c mice and human peripheral blood lymphocytes.

Fararjeh M, Mohammad MK, Bustanji Y, Alkhatib H, Abdalla S. Fararjeh M, et al. Among authors: bustanji y. Int Immunopharmacol. 2008 Feb;8(2):341-50. doi: 10.1016/j.intimp.2007.10.018. Epub 2007 Nov 20. Int Immunopharmacol. 2008. PMID: 18182250

7

Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.

Mohammad MK, Al-Masri IM, Taha MO, Al-Ghussein MA, Alkhatib HS, Najjar S, Bustanji Y. Mohammad MK, et al. Among authors: bustanji y. Eur J Pharmacol. 2008 Apr 14;584(1):185-91. doi: 10.1016/j.ejphar.2008.01.019. Epub 2008 Jan 30. Eur J Pharmacol. 2008. PMID: 18295757

8

Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.

Taha MO, Bustanji Y, Al-Ghussein MA, Mohammad M, Zalloum H, Al-Masri IM, Atallah N. Taha MO, et al. Among authors: bustanji y. J Med Chem. 2008 Apr 10;51(7):2062-77. doi: 10.1021/jm7009765. Epub 2008 Mar 7. J Med Chem. 2008. PMID: 18324764

9

A comparative study of first-derivative spectrophotometry and column high-performance liquid chromatography applied to the determination of repaglinide in tablets and for dissolution testing.

AlKhalidi BA, Shtaiwi M, AlKhatib HS, Mohammad M, Bustanji Y. AlKhalidi BA, et al. Among authors: bustanji y. J AOAC Int. 2008 May-Jun;91(3):530-5. J AOAC Int. 2008. PMID: 18567297

10

Modulation of buspirone HCl release from hypromellose matrices using chitosan succinate: implications for pH-independent release.

Alkhatib HS, Aiedeh KM, Bustanji Y, Hamed S, Mohammad MK, Alkhalidi B, Najjar S. Alkhatib HS, et al. Among authors: bustanji y. Eur J Pharm Biopharm. 2008 Nov;70(3):804-12. doi: 10.1016/j.ejpb.2008.06.017. Epub 2008 Jun 26. Eur J Pharm Biopharm. 2008. PMID: 18625308

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

120 results

Search Page